CA-CITY-OF-HOPE
1.4.2021 16:02:12 CEST | Business Wire | Press release
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, today announced that it will extend its leading-edge cancer expertise to South America via an education agreement with Hospital Israelita Albert Einstein, a top cancer center in Latin America.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210401005185/en/
The three-year agreement calls for City of Hope to share its specialized cancer expertise with Hospital Israelita Albert Einstein’s oncology residents and clinical staff. City of Hope will provide educational experiences and host multidisciplinary tumor boards. Both institutions will explore potential innovative collaborations in precision oncology and research.
“This agreement marks another milestone moment, allowing City of Hope to extend its mission to eliminate cancer to a new continent,” said Harlan Levine , M.D., president of strategy and business ventures at City of Hope, which is headquartered near Los Angeles.
“Hospital Israelita Albert Einstein has an exceptional medical team,” Levine added. “City of Hope will offer our best-in-class expertise as a comprehensive cancer center to both their residents in training and clinical staff. We hope to collaborate with our Latin American colleagues to improve cancer care outcomes not only in São Paulo, but also throughout Brazil and Latin America.”
Among other services, City of Hope will provide a virtual multidisciplinary tumor board that will initially focus on gastrointestinal, genitourinary, lung and brain cancers. Hospital Israelita Albert Einstein physicians will share specific patient cases with complex issues involving molecular diagnostics, immunotherapy and innovations in cancer care delivery for review and discussion. City of Hope will also provide educational webinars and offer professional training on topics such as genetic testing, supportive care services and nursing.
Sidney Klajner, M.D., Ph.D., president of Hospital Israelita Albert Einstein, said, “We will incorporate City of Hope’s multidisciplinary approach to oncology precision medicine to address the cancer burden in Brazil. Together with City of Hope, we hope to collaborate on molecular diagnostics and innovative care advancements for the benefit of patients in Latin American and beyond.”
Hospital Israelita Albert Einstein has been ranked as the best hospital in Latin America by the America Economia Business Intelligence Unit for 12 years in a row. Additionally, it is positioned 36th overall globally and 21st for specialized oncology on Newsweek’s ranking of the World’s Best Hospitals 2021.
This collaborative agreement was made possible through efforts by City of Hope’s Center for International Medicine (CIM), which seeks to collaborate with international organizations to improve cancer and diabetes care for more people worldwide. CIM works with governments, hospitals, private companies and investors, and offers a range of services in the areas of clinical research and innovation, education and professional development.
About City of Hope
City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy . City of Hope’s translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies, and numerous breakthrough cancer drugs are based on technology developed at the institution. Translational Genomics Research Institute (TGen) became a part of City of Hope in 2016. AccessHope TM , a wholly owned subsidiary, was launched in 2019, dedicated to serving employers and their health care partners by providing access to City of Hope’s exceptional cancer expertise. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nation’s “Best Hospitals” in cancer by U.S. News & World Report. Its main campus is located near Los Angeles, with additional locations throughout Southern California and in Arizona. For more information about City of Hope, follow us on Facebook , Twitter , YouTube or Instagram .
About Hospital Israelita Albert Einstein
Hospital Israelita Albert Einstein is a not-for-profit health care system based in São Paulo, Brazil. It encompasses activities in health care delivery, teaching, research, innovation and consultancy. In the private setting, the system manages a 600-bed general hospital and 10 satellite units spread around the greater metropolitan area of São Paulo and is dedicated to diagnostics and ambulatory medicine. In the public setting, the system manages two hospitals, with 600 beds in total and 24 ambulatory units. In 1999, the hospital became the first hospital outside of the U.S. to be accredited by Joint Commission International. It is currently the strategic partner of the Institute for Healthcare Improvement in Latin America.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210401005185/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hyper Brings its Latest Range of Power, Connectivity and MacBook Accessories to IFA 20264.9.2026 07:00:00 CEST | Press release
The latest additions to Hyper's portfolio make everyday mobile setups more personal, portable and productive across work, creating and travel Messe Berlin – IFA 2026 (Hall 5.2, Stand 179) – Hyper®, an innovator of mobile accessories for Apple users, creators and mobile professionals, will showcase its latest lineup at IFA 2026, designed to make everyday mobile setups more personal, portable and productive across work, creating and travel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903870923/en/ Discover Hyper's latest MacBook accessories, power and connectivity solutions debuting at IFA 2026 Building on essential MacBook Neo accessories, the range expands across portable charging, privacy, workspace connectivity and carry solutions, led by HyperJuice Flex, Hyper’s colourful and accessible collection designed to make everyday power more portable and personal. “At IFA, we’re introducing an everyday ecosystem built aroun
Mainstay Medical Announces Two-Year Outcomes from RESTORE Clinical Trial of ReActiv8®3.9.2026 22:30:00 CEST | Press release
ReActiv8® Restorative Neurostimulation™ treatment group showed sustained improvements in measures of disability, pain and quality of life from the one-year to the two-year timepoints.83% of control group patients elected to cross over and receive ReActiv8 therapy after the one-year assessment.After one year of ReActiv8 therapy, the outcomes in the crossover group were indistinguishable from the treatment group at the same time point, confirming the effect is reproducible, robust, and not cohort specific. Mainstay Medical Holdings plc today announced the publication of the two-year assessment results from the RESTORE randomized clinical trial of ReActiv8 for the treatment of intractable chronic low back pain. The data show continued improvements in back pain-related disability, pain and quality of life in the ReActiv8 treatment group, and improvements after one year of ReActiv8 therapy in the crossover group that were indistinguishable from the improvements shown by the treatment group
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)3.9.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to thirty-one newly hired non-executive employees. The equity awards were granted on September 1, 2026 and consisted of options to purchase an aggregate of 280,600 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 133,500 shares. The options have an exercise price per share equal to $13.24, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restr
Lenovo Advances Hybrid AI Across New Personal and Enterprise Technology3.9.2026 18:00:00 CEST | Press release
Lenovo announces expanded Lenovo and Motorola Qira experiences and availability, new Yoga, Idea, Think, and Motorola devices, and concepts that explore the next era of more personal, connected technology. Today at Lenovo™ Innovation World during IFA 2026, Lenovo unveiled a new portfolio of personal and enterprise technology, showing how its Hybrid AI strategy is moving from vision to practical experiences across devices, infrastructure, services, and the everyday moments that connect them. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903555953/en/ Lenovo Innovation World at IFA 2026 The announcements bring together Lenovo’s “one personal AI, multiple devices” approach with enterprise technology that helps organizations turn data into insights and value. They span personal AI across PCs, smartphones, tablets, and wearables; creator and consumer devices that adapt to different ways of working and expressing ideas; and bus
Bahrain Signs its Participation Contract for Expo 2030 Riyadh3.9.2026 17:45:00 CEST | Press release
The Kingdom of Bahrain has signed its Participation Contract for Expo 2030 Riyadh, marking a new phase in preparations for its participation in the World Expo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903144412/en/ His Excellency Sheikh Khalifa bin Ahmed Al Khalifa, President of the Bahrain Authority for Culture and Antiquities, and Talal Al-Marri, Chief Executive Officer of Expo 2030 Riyadh, at the ceremony. The agreement provides the formal framework for Bahrain’s participation in Expo 2030 Riyadh, enabling preparations to advance across the key organizational and operational aspects of its presence throughout the six-month event, including the development of its pavilion, programmes and visitor experiences. The Participation Contract was signed in Bahrain by Talal Al-Marri, Chief Executive Officer of Expo 2030 Riyadh, on behalf of Expo 2030 Riyadh, and His Excellency Sheikh Khalifa bin Ahmed Al Khalifa, President
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
